Analyst available to comment on the market forecast for the drug

Andrea S. Witt, Ph.D., analyst at Decision Resources, is available to discuss the impact of the Food and Drug Administration's re-approval of Biogen Idec's Tysabri for the treatment of multiple sclerosis (MS).

The Food and Drug Administration today gave Biogen Idec the go-ahead to resume sales of Tysabri, the multiple sclerosis drug that was pulled off the market 16 months ago when patients in clinical trials developed unexpected side effects.

  Dr. Witt can provide:   * A new forecast for the drug over the next ten years based on primary     market research with MS specialists in the United States and in Europe.     Will patients and neurologists use a highly efficacious drug with rare     lethal side effects?    * Implications for the current therapies in the MS drug market, namely the     interferon-betas and glatiramer acetate: will these drugs retain their     market dominance over the next ten years now that Tysabri has been     re-approved in the United States?    * How will Tysabri fare in the MS market once oral therapies for the     treatment of MS launch in the United States and in Europe?  

Dr. Witt is a senior analyst for the Central Nervous System Disorders Service at Decision Resources. Prior to joining the company, Dr. Witt studied the interaction between the delta-catenin and presenilin proteins in Alzheimer's disease at Brigham and Women's Hospital/Harvard Medical School, in Boston. Dr. Witt holds a Ph.D. in Neuroscience from the University of Texas Southwestern Medical Center in Dallas, where she conducted research and published articles investigating the relationship between oligodendrocytes and neuronal development in the Central Nervous System.

To receive the article or talk with Dr. Witt, please contact Liz Marshall at 781-296-2563 or

About Decision Resources

Decision Resources, Inc. ( is a world leader in market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

For more information, contact:

Elizabeth Marshall of Decision Resources, Inc., +1-781-296-2563,

PRNewswire -- June 5

SOURCE: Decision Resources, Inc.

New Drugs and Continued Uptake of Enbrel and Humira will Drive Rheumatoid Arthritis Treatment Market to More Than $10 Billion

View Now